ESPPancreatic ductal adenocarcinoma is one of the most lethal cancers. A major reason is the high prevalence of KRAS mutations, which help tumors grow and often make them difficult to treat. Although scientists have recently developed therapies aimed at certain KRAS mutations, many patients still lack effective treatment options. As a result, researchers continue searching for therapies that can work across a wider range of KRAS-driven cancers.
In the new study, investigators examined a group of experimental compounds called polyisoprenylated cysteinyl amide inhibitors (PCAIs). These compounds were originally created to interfere with abnormal KRAS signaling. Using pancreatic cancer cells carrying KRAS mutations, the team studied how PCAIs influence cancer cell survival, movement, invasion, and the signaling pathways involved in tumor development.
Know more: https://www.sciencedaily.com/releases/2026/06/260622091512.htm
